CRA enters strategic alliance with Quintiles

Tuesday, November 27, 2012 11:42 AM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a community-based network of clinical trial sites, has entered into a strategic agreement  with CRO Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and quality data.

CRA, which operates 38 sites across 17 geographic markets, is the first therapeutically aligned network of family medicine community-based sites selected by Quintiles for a strategic alliance.

“The core value and principal purpose of Clinical Research Advantage is to improve the lives of patients through the development of new medical therapies,” said Mark S. Hanley, CRA’s CEO. “Working with Quintiles will allow CRA to conduct an increased number of community-based trials with unparalleled accuracy and safety.”

“Clinical Research Advantage impressed us with their high standards for quality, high patient enrollments and exceptional study start-up abilities,” said Lindy Jones, senior vice president, integrated site services for Quintiles. “Many chronic conditions such as diabetes and heart disease are now managed in the community. It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society.”

Founded in 1992, CRA is a trial management organization that has completed more than 1,800 clinical trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs